Merck is testing Keytruda in combinations with Celgene's Revlimid and Pomalyst as a treatment for multiple myeloma. Read more
The MDL revolves around settlements Merck reached with Upsher-Smith and Baxter International Inc. unit ESI Lederle Inc. Read more
Lawyers in our firm have handled a good number of Fosamax cases. Read more
The patent, issued in 2009, is for a compound that Merck’s Idenix unit contends is the basis for all major treatments for hepatitis C. Read more
It would appear that Olympus in Japan knew of the dangers of the duodenoscopes not being able to be adequately disinfected. Read more
A New Jersey federal judge has granted final approval to the $1.06 billion settlement between Merck & Co. Inc. and the drug company’s investors to resolve multidistrict litigation (MDL)... Read more
The whistleblower allegedly started working for Merck in 1972 and for Genentech in 1986, leaving the latter company in February 2005. Read more
I have found that few people in the business world really understand how the pharmacy benefit managers operate. Read more
The United States Supreme Court has declined to review a California appellate court’s decision allowing a state law failure-to-warn claim to proceed against several generic drug manufacturer... Read more
As most of those who receive the Report and are familiar with our firm know, our Mass Torts Section was closely involved in the Vioxx litigation against Merck. Led by Andy Birchfield, who no... Read more
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.